Topline results were announced from a trial evaluating albuterol/budesonide inhaler in patients with intermittent or mild persistent asthma.

Two posters presented at the CHEST 2024 annual meeting underscore the importance of early identification and treatment of ...

"AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint" was originally created and published by ...

AstraZeneca’s BATURA phase IIIb trial of Airsupra in patients with intermittent or mild persistent asthma meets primary endpoint: Cambridge, UK Tuesday, October 8, 2024, 09:00 H ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...

AstraZeneca's Airsupra (albuterol/budesonide) met the primary endpoint in the Phase III BATURA trial, significantly reducing ...

AstraZeneca’s inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk of severe asthma exacerbations in patients with intermittent or mild ...

AstraZeneca’s inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk of severe asthma exacerbations in patients with intermittent or mild ...

The phase 3b BATURA study showed Airsupra (albuterol/budesonide) achieved a statistically significant reduction in the risk of severe asthma exacerbations when used as needed for rescue therapy ...

A state legislative hearing Wednesday that lawmakers said was to review Louisiana’s response to the COVID-19 pandemic turned ...

Purpose: The effects of extreme temperatures on drug delivery of two albuterol sulfate hydrofluoroalkane, metered-dose inhalers (MDIs) were evaluated.Methods. Three Proventil HFA and three ...